Retraction
Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma
Paper Information
Record ID:
46949
Author(s):
Journal:
Publication Date:
October 13, 2014
Retraction Date:
August 11, 2023
(2.3 years years ago)
Subjects:
Institutions:
- Peter MacCallum Cancer Centre, East Melbourne
- University of Melbourne, Parkville, Victoria
- Queensland Institute of Medical Research
- School of Medicine, University of Queensland, Herston, Queensland, Australia
- Juntendo University School of Medicine, Tokyo, Japan
- Peter MacCallum Cancer Centre, East Melbourne
- University of Melbourne, Parkville, Victoria
Countries:
Article Type:
Publisher:
American Society of Clinical Oncology
Open Access:
Yes
PubMed ID:
Retraction PubMed ID:
Retraction Details
Retraction Reasons:
Nature of Retraction:
Retraction
Retraction Notice:
10.1200/JCO.23.01358Additional Notes:
Mark J Smyth has institutional finding of misconduct;
Citations (74)
74
Total Citations7
Post-Retraction(9.5%)
67
Pre-Retraction0
Same DayPost-Retraction Citation Analysis
0
Within 30 days
5
Within 1 year
0
After 2+ years
509
Days since retraction (latest)
RANK/RANKL Signaling Pathway in Breast Development and Cancer
Gema Pérez-Chacón, Patricia G. Santamarı́a, Jaime Redondo-Pedraza et al. (4 authors)
Advances in experimental medicine and biology
Published: Jan 2025
1 citation
1 citation
509 days after retraction
Synergistic effect between denosumab and immune checkpoint inhibitors (ICI)? A retrospective study of 268 patients with ICI and bone metastases
E. Mabrut, S. Mainbourg, Julien Péron et al. (11 authors)
Journal of bone oncology
Open Access
Published: Sep 2024
1 citation
1 citation
407 days after retraction
Targeting the NF-κB pathway as a potential regulator of immune checkpoints in cancer immunotherapy
Nasim Ebrahimi, Al‐Hasnawi Rasool Riyadh Abdulwahid, Atena Mansouri et al. (11 authors)
Cellular and Molecular Life Sciences
Open Access
Published: Feb 2024
37 citations
37 citations
202 days after retraction
Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Hewitt Chang, Jaqueline Marquez, Brandon K. Chen et al. (18 authors)
Cancer Immunology Research
Open Access
Published: Jan 2024
5 citations
5 citations
168 days after retraction
Spectrum of Treg and Self-Reactive T cells: Single Cell Perspectives from Old Friend HTLV-1
Masahiro Ono, Yorifumi Satou
Discovery Immunology
Open Access
Published: Jan 2024
5 citations
5 citations
143 days after retraction
Repurposing drugs for solid tumor treatment: focus on immune checkpoint inhibitors
Qingxu Liu, L. Li, Qin Wan et al. (4 authors)
Cancer Biology and Medicine
Open Access
Published: Nov 2023
3 citations
3 citations
87 days after retraction
Discovery of RANKL and the current and future impact of its research
Hisataka Yasuda
Folia Pharmacologica Japonica
Published: Apr 2023
103 days before retraction
Immunotherapy as a potential treatment approach for currently incurable bone metastasis
Yang Yu, Jenna Ollodart, Kelly F. Contino et al. (4 authors)
Journal of Bone and Mineral Metabolism
Open Access
Published: Feb 2023
6 citations
6 citations
184 days before retraction
Determining role of thymus in immune pathogenesis of autoimmune, oncological and infectious diseases
Kozlov Va
Medical Immunology (Russia)
Open Access
Published: Feb 2023
9 citations
9 citations
186 days before retraction
Combination of immunotherapy, radiotherapy and denosumab as the best approach even for NSCLC poor prognosis patients: a case report with strong response, prolonged survival and a review of literature
Marco De Felice, Giacinto Turitto, C. Borrelli et al. (5 authors)
Current Problems in Cancer
Published: Jan 2023
3 citations
3 citations
208 days before retraction
RANKL and RANK in Cancer Therapy
Masahiro Onji, Josef Penninger
Physiology
Open Access
Published: Dec 2022
5 citations
5 citations
248 days before retraction
Bone Metastasis of Breast Cancer: Molecular Mechanisms and Therapeutic Strategies
Lulian Pang, Gan Chen, Jian Xu et al. (10 authors)
Cancers
Open Access
Published: Nov 2022
35 citations
35 citations
262 days before retraction
Impact of Bone Metastases on Patients with Renal Cell Carcinoma or Melanoma Treated with Combotherapy Ipilimumab Plus Nivolumab
Félix Pham, Samy Belkaïd, Denis Maillet et al. (6 authors)
Biomedicines
Open Access
Published: Oct 2022
6 citations
6 citations
284 days before retraction
Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis
Francesco Pantano, Flavia Tramontana, Michele Iuliani et al. (15 authors)
Journal of bone oncology
Open Access
Published: Oct 2022
16 citations
16 citations
287 days before retraction
Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa-Β ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma
Sonia Simonetti, Michele Iuliani, Marco Stellato et al. (8 authors)
Journal for ImmunoTherapy of Cancer
Open Access
Published: Sep 2022
12 citations
12 citations
344 days before retraction
Improved Characteristics of RANKL Immuno-PET Imaging Using Radiolabeled Antibody Fab Fragments
Jonatan Dewulf, Ivanna Hrynchak, Sarah Geudens et al. (10 authors)
Pharmaceutics
Open Access
Published: Apr 2022
6 citations
6 citations
472 days before retraction
Roles of the RANKL–RANK Axis in Immunity—Implications for Pathogenesis and Treatment of Bone Metastasis
Bo Li, Pengru Wang, Jian Jiao et al. (6 authors)
Frontiers in Immunology
Open Access
Published: Mar 2022
48 citations
48 citations
508 days before retraction
RANKL biology
Noriko Takegahara, Hyunsoo Kim, Yongwon Choi
Bone
Open Access
Published: Feb 2022
81 citations
81 citations
541 days before retraction
Therapeutic Interruption of T Cell Development Generates High-Affinity T Cells That Escape Exhaustion and Improve Cancer Immunotherapy
Erica Dhuey, Olivia Oldridge, Roshan Ravishankar et al. (7 authors)
bioRxiv (Cold Spring Harbor Laboratory)
Open Access
Published: Jan 2022
2 citations
2 citations
567 days before retraction
Recent trends in cancer immunotherapy: Pathways and inhibitors
G Vidya
Elsevier eBooks
Published: Jan 2022
587 days before retraction
Low Serum Levels of Soluble Receptor Activator of Nuclear Factor κ B Ligand (sRANKL) Are Associated with Metabolic Dysregulation and Predict Long-Term Mortality in Critically Ill Patients
Tobias Puengel, B. Weber, Theresa H. Wirtz et al. (16 authors)
Diagnostics
Open Access
Published: Dec 2021
1 citation
1 citation
591 days before retraction
Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation
Chang Liu, Miao Wang, Changli Xu et al. (7 authors)
Journal of Immunology Research
Open Access
Published: Nov 2021
45 citations
45 citations
621 days before retraction
The Roadmap of RANKL/RANK Pathway in Cancer
Sandra Casimiro, Guilherme Vilhais, Inês Gomes et al. (4 authors)
Cells
Open Access
Published: Aug 2021
42 citations
42 citations
737 days before retraction
Tumor microenvironment in giant cell tumor of bone: evaluation of PD-L1 expression and SIRPα infiltration after denosumab treatment
Yu Toda, Kenichi Kohashi, Hidetaka Yamamoto et al. (20 authors)
Scientific Reports
Open Access
Published: Jul 2021
17 citations
17 citations
752 days before retraction
Osteoimmuno-Oncology: Therapeutic Opportunities for Targeting Immune Cells in Bone Metastasis
Tiina E. Kähkönen, Jussi M. Halleen, Jenni Bernoulli
Cells
Open Access
Published: Jun 2021
20 citations
20 citations
785 days before retraction
Cancer Treatment–Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy
Anna Diana, Francesca Carlino, Emilio Francesco Giunta et al. (9 authors)
Current Treatment Options in Oncology
Open Access
Published: Apr 2021
37 citations
37 citations
847 days before retraction
Discovery of the RANKL/RANK/OPG system
Hisataka Yasuda
Journal of Bone and Mineral Metabolism
Published: Jan 2021
181 citations
181 citations
952 days before retraction
Role of RANKL in cancer development and metastasis
Kazuo Okamoto
Journal of Bone and Mineral Metabolism
Published: Jan 2021
22 citations
22 citations
952 days before retraction
RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity
Hong Wang, Reading Ashton, Jonathan A. Hensel et al. (8 authors)
Molecular Cancer Therapeutics
Open Access
Published: Nov 2020
6 citations
6 citations
998 days before retraction
The Role of the RANKL/RANK Axis in the Prevention and Treatment of Breast Cancer with Immune Checkpoint Inhibitors and Anti-RANKL
Aristofania Simatou, Panagiotis Sarantis, Evangelos Koustas et al. (5 authors)
International Journal of Molecular Sciences
Open Access
Published: Oct 2020
23 citations
23 citations
1031 days before retraction
An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival
Francesco Mannavola, Mario Mandalà, Annalisa Trama et al. (33 authors)
Frontiers in Oncology
Open Access
Published: Sep 2020
23 citations
23 citations
1060 days before retraction
Targeting the RANKL/RANK/OPG Axis for Cancer Therapy
Jie Ming, Shane J. F. Cronin, Josef Penninger
Frontiers in Oncology
Open Access
Published: Aug 2020
58 citations
58 citations
1099 days before retraction
Repurposing denosumab in lung cancer beyond counteracting the skeletal related events: an intriguing perspective
Maria V. Deligiorgi, Dimitrios T. Trafalis
Expert Opinion on Biological Therapy
Published: Jul 2020
6 citations
6 citations
1124 days before retraction
Cytotoxic T lymphocyte antigen-4 (CTLA-4) expression in chordoma and tumor-infiltrating lymphocytes (TILs) predicts prognosis of spinal chordoma
Guanping He, X. Liu, Xiaoyu Pan et al. (5 authors)
Clinical & Translational Oncology
Published: Jun 2020
16 citations
16 citations
1162 days before retraction
Successful Treatment of a Patient with anti-PD1 Antibody-Resistant Advanced Mucosal Melanoma with Nivolumab, Ipilimumab plus Denosumab Combination Therapy
Taku Fujimura, Yumi Kambayashi, Kentaro Ohuchi et al. (8 authors)
Case Reports in Oncology
Open Access
Published: Mar 2020
5 citations
5 citations
1235 days before retraction
Combining immune checkpoint inhibitors with denosumab: a new era in repurposing denosumab in oncology?
Maria V. Deligiorgi, Mihalis I. Panayiotidis, Dimitrios T. Trafalis
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
Published: Jan 2020
2 citations
2 citations
1318 days before retraction
Erfolgreiche Behandlung multipler Melanommetastasen mit einer Kombinationstherapie aus Nivolumab, Ipilimumab und Denosumab
Saaya Yoshida, Taku Fujimura, Yumi Kambayashi et al. (6 authors)
Kompass Dermatologie
Published: Jan 2020
1318 days before retraction
The Non-Bone-Related Role of RANK/RANKL Signaling in Cancer
Peter A. van Dam, Yannick Verhoeven, Xuan Bich Trinh
Advances in experimental medicine and biology
Published: Jan 2020
6 citations
6 citations
1318 days before retraction
Drugs repurposed to potentiate immunotherapy for cancer treatment
Kenneth K.W. To, Yong‐Yeon Cho
Elsevier eBooks
Published: Jan 2020
3 citations
3 citations
1318 days before retraction
Reply:
Yoshitaka Arase, Tatehiro Kagawa, Atsushi Tanaka
Hepatology
Open Access
Published: Dec 2019
1329 days before retraction
Pharmacodynamics of Pre-Operative PD1 Checkpoint Blockade and Receptor Activator of NFkB Ligand (RANKL) Inhibition in Non-Small Cell Lung Cancer (NSCLC): study protocol for a multicentre open-label phase 1B/2 translational trial (POPCORN)
Elizabeth Ahern, Annette Cubitt, E Ballard et al. (10 authors)
Research Square (Research Square)
Open Access
Published: Dec 2019
1348 days before retraction
Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN)
Elizabeth Ahern, Annette Cubitt, E Ballard et al. (10 authors)
Trials
Open Access
Published: Dec 2019
26 citations
26 citations
1349 days before retraction
Paper citing Combination Anti-CTLA-4 and Anti-RANKL in Metastat...
Unknown Authors
Unknown Journal
Published: Dec 2019
1349 days before retraction
Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy
Saaya Yoshida, Taku Fujimura, Yumi Kambayashi et al. (6 authors)
Case Reports in Oncology
Open Access
Published: Oct 2019
7 citations
7 citations
1381 days before retraction
Immune Regulation of Tumors in Bone
Biancamaria Ricci, Sarah Zimmerman, Wei Wang et al. (4 authors)
Elsevier eBooks
Published: Oct 2019
1402 days before retraction
Bone metastases in the era of targeted treatments: insights from molecular biology
Jonatan Dewulf, Christel Vangestel, Yannick Verhoeven et al. (7 authors)
The Quarterly Journal of Nuclear Medicine and Molecular Imaging
Open Access
Published: Sep 2019
8 citations
8 citations
1440 days before retraction
Extraskeletal effects of RANK ligand
Andy Göbel, Tilman D. Rachner, Lorenz C. Hofbauer
Elsevier eBooks
Published: Aug 2019
1449 days before retraction
Pharmacodynamics of Pre-Operative PD1 Checkpoint Blockade and Receptor Activator of NFkB Ligand (RANKL) Inhibition in Non-Small Cell Lung Cancer (NSCLC): study protocol for a multicentre open-label phase 1B/2 translational trial (POPCORN)
Elizabeth Ahern, Annette Cubitt, E Ballard et al. (10 authors)
Research Square (Research Square)
Open Access
Published: Jul 2019
2 citations
2 citations
1481 days before retraction
Osteoblasts contribute to a protective niche that supports melanoma cell proliferation and survival
Jennifer Ferguson, Daniel J. Wilcock, Sophie McEntegart et al. (8 authors)
Pigment Cell & Melanoma Research
Open Access
Published: Jul 2019
9 citations
9 citations
1484 days before retraction
Quick Stats
Total Citations:
74
Years Since Retraction:
2.3 years
Open Access:
Yes
Last Checked:
Jul 24, 2025